The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and ...

The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.